Preexposure prophylaxis for HIV infection: Healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US

Southern Medical Journal

Volumn 105, Issue 4, 2012, Pages 199-206

  Tripathi, Avnish ^a,b,c,d   Ogbuanu, Chinelo ^a,b,c,d   Monger, Mauda ^a,b,c,d   Gibson, James J ^a,b,c,d   Duffus, Wayne A ^a,b,c,d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MISSISSIPPI STATE DEPARTMENT OF HEALTH   (United States)

^c Bureau of Disease Control   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral drugs; attitudes; beliefs; health knowledge; HIV healthcare providers; HIV preexposure prophylaxis; HIV prevention

Indexed keywords

ADULT; ARTICLE; CAUCASIAN; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ETHNICITY; FAMILY PLANNING; FEMALE; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNOWLEDGE; MALE; MEDICAL EDUCATION; NEGRO; OCCUPATION; RACE; SAFETY; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; VIRUS TRANSMISSION;

CONTINENTAL POPULATION GROUPS; DATA COLLECTION; ETHNIC GROUPS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MISSISSIPPI; PHYSICIANS; PUBLIC HEALTH NURSING; SOUTH CAROLINA;

EID: 84859639373     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31824f1a1b     Document Type: Article

References (31)

1. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1-207; quiz CE1-4.
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
3. Lampe MA, Smith DK, Anderson GJ, et al. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488.e1-488.e8.
4. Centers for Disease Control and Prevention. Goals and objectives of the CDC HIV prevention strategic plan: extended through 2010. Short-term milestone 3, objective 1. http://www.cdc.gov/hiv/resources/reports/psp/goal-objective.htm. Accessed December 28, 2010.
5. Centers for Disease Control and Prevention. HIV and AIDS in the United States. http://www.cdc.gov/hiv/resources/factsheets/us.htm. Accessed July 20, 2010.
6. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60:65-68.
7. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010;51:725-731.
8. Gostin LO, Kim SC. Ethical allocation of preexposure HIV prophylaxis. JAMA 2011;305:191-192.
9. Ramjee G, Kamali A, McCormack S. The last decade of microbicide clinical trials in Africa: from hypothesis to facts. AIDS 2010;24(4 suppl):S40-S49.
10. Michael NL. Oral preexposure prophylaxis for HIV - another arrow in the quiver? N Engl J Med 2010;363:2663-2665.
11. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298.
12. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008;372:1857-1858.
13. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168.
14. Fleming PL, Lansky A, Lee LM, et al. The epidemiology of HIV/AIDS in women in the southern United States. Sex Transm Dis 2006;33:S32-S38. (Pubitemid 43964742)
15. AVAC. PrEP resources. http://www.avac.org/ht/d/sp/i/354/pid/354. Accessed May 12, 2011.
16. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
17. Brooks RA, Kaplan RL, Lieber E, et al. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care 2011;23:1136-1145.
18. Voetsch AC, Heffelfinger JD, Begley EB, et al. Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2007;46:378-380. (Pubitemid 350287373)
19. Whiteside YO, Harris T, Scanlon C, et al. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDS 2011;25:365-370.
20. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-524.
21. Mayer KH, Safren SA, Gordon CM. HIV care providers and prevention: opportunities and challenges. J Acquir Immune Defic Syndr 2004;37(2 suppl):S130-S132.
22. Lindley LL, Coleman JD, Gaddist BW, et al. Informing faith-based HIV/AIDS interventions: HIV-related knowledge and stigmatizing attitudes at Project F.A.I.T.H. churches in South Carolina. Public Health Rep 2010;125(1 suppl):12-20.
23. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010;13:24.
24. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 2007;370:89-93. (Pubitemid 47033881)
25. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009;50:77-83.
26. Golub SA, Kowalczyk W, Weinberger CL, et al. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010;54:548-555.
27. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-792. (Pubitemid 38535007)
28. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71.
29. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). http://pag.aids2010.org/Abstracts. aspx?AID=17777. Accessed February 6, 2012.
30. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5:e28.
31. Centers for Disease Control and Prevention Fact Sheets. Pre-exposure prophylaxis (PrEP) for HIV prevention: planning for potential implementation in the U.S. http://www.cdc.gov/hiv/resources/factsheets/index.htm#Prevention. Accessed May 21, 2011.